Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 94
Selected: 0
NCT IDTitle
NCT02138786Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT03555422Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT07200102Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT02741388A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
NCT04843579Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
NCT02416908Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT04519476Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
NCT02384850Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
NCT02213133Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT02351505Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
NCT05177276Selinexor Combination Ph 1 Study
NCT02403310A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
NCT07215832Karyopharm Expanded Access Program for Selinexor
NCT04856189Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
NCT05170789Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT04562389Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT02186834Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02249091A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT03732703Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT02303392Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
NCT01986348Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT04782687Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT02025985Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
NCT02137356Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
NCT05820763Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
NCT04355676Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
NCT02228525Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
NCT04768881Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT03042819Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
NCT02702492PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
NCT02091245Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT03880123Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
NCT07447817Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT02471911KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT03191981Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
NCT05597345Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
NCT04914845KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT01607892Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT02431364Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
NCT03110562Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03193437Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
NCT02343042Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02250885KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
NCT02146833SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT05530421Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma